AI assistant
Cytek Biosciences, Inc. — Director's Dealing 2025
Mar 6, 2025
32966_dirs_2025-03-06_819357b6-efd5-460f-97dc-478074bd3294.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2025-03-04
Reporting Person: McCombe William D. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-04 | Employee Stock Option (right to buy) | $4.31 | A | 330882 | Acquired | 2035-03-04 | Common Stock (330882) | Direct |
| 2025-03-04 | Restricted Stock Units | $ | A | 208816 | Acquired | Common Stock (208816) | Direct |
Footnotes
F1: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested.
F2: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested.